What Happens
There is no single EU-wide switch that flips the day the transition period ends. EUDAMED itself does not block a device record from existing, and no automated fine gets issued. What changes is the legal basis for the device to be on the market: after the transition period set by Regulation (EU) 2024/1860 ends, a device that was on the market under the legacy derogation and still has no valid EUDAMED registration has no remaining legal pathway for continued sale in the EU.
From that point, enforcement is a national competent authority function, not an automatic EUDAMED function. A competent authority has to identify the non-compliant device, open a case, evaluate it under MDR Article 94, and follow through with the corrective-action procedure in Article 97, or Article 95 for unacceptable-risk devices, covered below. In practice this means the consequences are not instant or uniform. They depend on which Member State's authority notices first, how backlogged that authority is, and whether the device is judged to present an unacceptable risk.
The Legal Mechanism
The November 27, 2026 date is not written into the text of the MDR itself. It is the product of a transition-period mechanism added by Regulation (EU) 2024/1860, which amended MDR Article 123(3) to allow EUDAMED to go live module by module rather than all at once. Under that mechanism, each time the Commission publishes a notice in the Official Journal confirming a module is functional, two clocks start: a six-month transition period before use of the module becomes mandatory for newly placed devices, and a twelve-month period for devices already on the market under a valid legacy certificate to complete registration.
Commission Decision (EU) 2025/2371, published November 27, 2025, confirmed functionality for four modules: economic operator (actor) registration, the UDI/device database, notified bodies and certificates, and market surveillance. That notice started both clocks. The six-month date, May 28, 2026 for newly placed devices, is one the Commission has stated directly. For the twelve-month legacy-device window, the Commission has not published a standalone notice naming a calendar date the way it did for May 28, so industry sources compute it from the transition period and land a day apart, November 27 or November 28, 2026. This guide uses November 27, 2026, consistent with our guide to the November 2026 deadline, which covers who falls into each category and what data each needs.
The Market Surveillance Procedure
MDR Chapter VII gives competent authorities a three-step structure for a device that turns out to be non-compliant, and which article governs changes how fast anything actually happens.
The evaluation duty (Article 94)
MDR Article 94 requires a competent authority that suspects a device is non-compliant, including a device missing its EUDAMED registration, to evaluate it against the applicable MDR requirements. This step does not itself authorize market action. It determines which of the two procedural tracks below applies.
Other non-compliance, with a correction period (Article 97)
MDR Article 97 covers a device that does not comply with a requirement but is not judged to present an unacceptable risk to health or safety. In that case the competent authority must first require the economic operator to correct the non-compliance within a period that is clearly defined, communicated, and proportionate to the non-compliance. Only if that period passes without correction does the Member State move to restrict or prohibit the device being made available, or ensure it is recalled or withdrawn.
Unacceptable risk, no correction window (Article 95)
MDR Article 95 is the faster track. Where the Article 94 evaluation finds the device presents an unacceptable risk to health or safety, the competent authority can require the manufacturer to take corrective action, and restrict, withdraw, or recall the device within a reasonable period, without the correction window Article 97 provides. Missing an EUDAMED registration deadline does not, by itself, establish unacceptable risk; that is a separate clinical and safety determination.
Penalties Are Set by Member States
MDR Article 113 does not set an EU-wide fine schedule. It requires each Member State to lay down its own rules on penalties for MDR infringements and to notify the Commission of those rules, with the only substantive EU-level constraint being that the penalties are effective, proportionate, and dissuasive. That means the financial consequence of a missed EUDAMED deadline, if a Member State pursues one, varies by which country's competent authority has jurisdiction over the manufacturer, Authorised Representative, or importer involved.
This guide does not attempt to list national penalty amounts. They are set and updated at Member State level, not by the Commission, and a figure correct today can be superseded by national legislation without an EU-level announcement. Manufacturers who want the applicable figure should check with the competent authority in the relevant Member State directly.
The May 2026 Precedent
The closest available precedent is not a prior EUDAMED deadline that has already produced enforcement cases; it is the May 28, 2026 mandatory-use date for the first four modules, including actor registration, which passed a little over two months before this guide was published. What is documented so far about that transition is procedural, not punitive.
Germany's BfArM disabled new product entries into DMIDS, its parallel national medical device database, on May 28, 2026, and now directs manufacturers to EUDAMED instead. MedTech Europe, the industry association, described the May 28 milestone as the point at which EUDAMED compliance became "an operational compliance requirement" without citing specific enforcement actions taken against non-compliant manufacturers.
Reporting available at the time of writing does not document a specific case of a competent authority completing an Article 97 or Article 95 action against a device solely for missing an EUDAMED registration deadline. That absence is not the same as a guarantee it will not happen for the November 27, 2026 deadline; it reflects how recently the first mandatory-use date passed and how the correction-period structure in Article 97 delays visible market action even where a case has opened.
If You Are Going to Miss It
For a manufacturer that will not have every device registered by November 27, 2026, the practical priority order follows directly from the Article 97 procedure above: a documented, in-progress correction is a materially different position than no registration activity at all.
- Confirm the manufacturer (and Authorised Representative, if non-EU) actor record is active first. Device registration cannot proceed without it, and it is the fastest thing to fix.
- Register the devices with the clearest, most complete data first. A partial portfolio registered is a stronger position under Article 97's proportionality standard than a complete portfolio still unregistered.
- Keep a dated record of registration progress and any blockers (for example, an issuing entity delay on a Basic UDI-DI). If a competent authority does open a case, that record is what demonstrates the non-compliance is being corrected.
- Contact the relevant competent authority directly if a structural blocker, not just workload, is causing the delay. Article 97 gives authorities discretion over what counts as a proportionate correction period.
Common Misconceptions
| Misconception | What the Regulation Actually Says |
|---|---|
| EUDAMED automatically blocks or flags a device the day the deadline passes | EUDAMED is a registration database; enforcement is a competent authority function under MDR Chapter VII, not something the system triggers on its own |
| There is a fixed EU-wide fine for missing the deadline | MDR Article 113 leaves penalties to each Member State, with only a general effective/proportionate/dissuasive standard set at EU level |
| Any non-compliance leads straight to market withdrawal | Article 97 requires a defined correction period first for non-compliance that does not present unacceptable risk; withdrawal follows only if that period lapses |
| November 27, 2026 is a new deadline unrelated to what already happened on May 28, 2026 | Both dates come from the same Regulation (EU) 2024/1860 transition mechanism, counted from the same November 27, 2025 functionality notice: six months for new-device mandatory use, twelve months for legacy-device registration |
The mechanism behind the November 2026 deadline is well documented; what happens after it passes for any specific device is not, because it depends on a national competent authority case that has not yet been publicly reported for a EUDAMED-registration issue. The safer planning assumption is the one MDR Article 97 already implies: a device with registration in progress is in a materially different position than one with none, regardless of which competent authority eventually looks at it.
Frequently Asked Questions
What actually happens the day after the EUDAMED registration deadline passes?
Nothing happens to the device record automatically. Regulation (EU) 2024/1860 and Commission Decision (EU) 2025/2371 set November 27, 2026 as the end of the transition period for devices already on the market, so a device without a valid EUDAMED registration after that date is in breach of the device-registration obligation in MDR Article 29 and has no legal basis for continued sale. Whether and how that gets enforced against a specific device depends on a national competent authority evaluating it under MDR Article 94 and then acting under Article 97, or Article 95 for unacceptable-risk devices.
Is there an automatic penalty or fine for missing the deadline?
No fixed EU-wide fine exists. MDR Article 113 leaves it to each Member State to set its own sanctions for non-compliance, with the only EU-level requirement being that those sanctions are effective, proportionate, and dissuasive. What applies to a specific manufacturer depends on which Member State's competent authority takes action.
Does a competent authority pull a device off the market immediately?
Not immediately, in the standard case. Under MDR Article 97, where a device does not comply but does not present an unacceptable risk, the competent authority must first give the economic operator a clearly defined, proportionate period to correct the non-compliance. Market restriction, recall, or withdrawal only follows if that period passes without correction. Article 95 applies a faster, more direct process, but only where the device presents an unacceptable risk to health or safety, which missing a registration deadline does not by itself establish.
Has this happened before with an earlier EUDAMED deadline?
The closest precedent is the mandatory-use date of May 28, 2026 for the first four EUDAMED modules, including actor (economic operator) registration, which passed roughly two and a half months before this guide was published. What is documented so far is procedural rather than punitive: Germany's BfArM disabled new entries into its parallel national device database (DMIDS) on May 28, 2026 and now requires EUDAMED instead, and industry sources describe the shift as an operational compliance requirement rather than reporting specific withdrawal or fine cases tied to it.
Does the November 27, 2026 deadline apply to devices placed on the market before May 28, 2026?
Yes. That is specifically what the deadline covers. Devices entering the EU market for the first time after May 28, 2026 already had to be registered before that first placement. November 27, 2026 is the separate, later deadline for devices already in distribution channels under valid conformity certificates as of the transition period.